Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* Premenopausal woman at screening.~* Body Mass Index ≥ 18 kg/m2.~* Menstrual cycles ≥ 21 days and ≤ 40 days.~* Presence of uterine fibroids.~* Heavy menstrual blood loss for each of the 2 menstrual periods assessed at screening using the alkaline hematin method.~Key Exclusion Criteria:~* The subject is pregnant or breast-feeding or is planning a pregnancy within the duration of the treatment period of the study.~* History of uterus surgery that would interfere with the study.~* The subject's condition is so severe that she will require surgery within 6 months regardless of the treatment provided.~* Undiagnosed abnormal uterine bleeding.~* Significant risk of osteoporosis or history of, or known osteoporosis or other metabolic bone disease.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OBE2109 dose 1 (100mg) + Placebo Add-back (Type: EXPERIMENTAL): None
- OBE2109 dose 1 (100mg) + Add-back (Type: EXPERIMENTAL): None
- OBE2109 dose 2 (200mg) + Placebo Add-back / OBE2109 dose 2 (200 mg) + Add-back (Type: EXPERIMENTAL): None
- OBE2109 dose 2 (200mg) + Add-back (Type: EXPERIMENTAL): None
- Placebo + Placebo Add-back / OBE2109 dose 3 (200mg) + Add-back (Type: PLACEBO_COMPARATOR): At W24, half of the patients switched to active treatment, while half remained on Placebo; the switch was defined at randomization.

Based on this trial design, predict the completion outcome and termination type (if applicable).